AKAO - Achaogen, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.7799
-0.0861 (-9.94%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.8660
Open0.8890
Bid0.8000 x 1000
Ask0.8200 x 2900
Day's Range0.7781 - 0.8900
52 Week Range0.7781 - 15.0000
Volume2,885,560
Avg. Volume1,344,909
Market Cap35.969M
Beta (3Y Monthly)0.87
PE Ratio (TTM)N/A
EPS (TTM)-4.1210
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Trade prices are not sourced from all markets
  • Does Achaogen, Inc. (NASDAQ:AKAO) Have A High Beta?
    Simply Wall St.2 days ago

    Does Achaogen, Inc. (NASDAQ:AKAO) Have A High Beta?

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Anyone researching Achaogen, Inc. (NASDAQ:AKAO) might want to consider theRead More...

  • GlobeNewswire2 days ago

    Achaogen Announces Publication of Plazomicin Phase 3 CARE Study Results in the New England Journal of Medicine

    Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that the New England Journal of Medicine has published the results from the Phase 3 CARE (Combating Antibiotic Resistant Enterobacteriaceae) study of plazomicin in a Letter to the Editor. In this published study, the efficacy and safety of plazomicin versus colistin was evaluated in patients with serious bloodstream infections or hospital-acquired/ventilator-associated bacterial pneumonia caused by carbapenem-resistant Enterobacteriaceae (CRE). ZEMDRI® (plazomicin) is an aminoglycoside administered as a once-daily, 30-minute intravenous (IV) infusion that has activity against certain Enterobacteriaceae.

  • GlobeNewswire2 days ago

    Achaogen Announces ZEMDRI® (plazomicin) Pivotal Phase 3 Study Results Published in the New England Journal of Medicine

    -- ZEMDRI is the only once-daily aminoglycoside therapy FDA-approved for use in complicated urinary tract infections (cUTI) -- -- Treatment with ZEMDRI resulted in a greater.

  • GlobeNewswire3 days ago

    Achaogen Announces Closing of $15 Million Underwritten Public Offering

    Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced the completion of its previously announced underwritten public offering of 15,000,000 shares of its common stock and accompanying short-term warrants to purchase up to 15,000,000 shares of its common stock and long-term warrants to purchase up to 15,000,000 shares of its common stock (collectively, the “warrants”). Each share of common stock was sold together with one short-term warrant to purchase one share of common stock and one long-term warrant to purchase one share of common stock, at a combined price to the public of $1.00 per share of common stock and accompanying warrants, for gross proceeds of $15.0 million and net proceeds of approximately $13.6 million after deducting underwriting discounts and commissions and estimated offering expenses payable by Achaogen.

  • GlobeNewswire3 days ago

    Achaogen Announces Presentations at Two Upcoming Investor Healthcare Conferences

    -- Leerink February 27, 2019 at 9:30 a.m. ET -- -- Cowen March 12, 2019 at 12:00 p.m. ET -- SOUTH SAN FRANCISCO, Calif., Feb. 20, 2019 -- Achaogen, Inc. (NASDAQ: AKAO), a.

  • GlobeNewswire8 days ago

    Achaogen Announces Pricing of $15 Million Underwritten Public Offering

    Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock and accompanying short-term warrants to purchase up to 15,000,000 shares of its common stock and long-term warrants to purchase up to 15,000,000 shares of its common stock (collectively, the “warrants”). Each share of common stock is being sold together with one short-term warrant to purchase one share of common stock and one long-term warrant to purchase one share of common stock, at a combined price to the public of $1.00 per share of common stock and accompanying warrants, for gross proceeds of $15 million, before deducting underwriting discounts and commissions and offering expenses payable by Achaogen.

  • GlobeNewswire9 days ago

    Achaogen Announces Proposed Public Offering of Common Stock

    Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Achaogen. In addition, Achaogen expects to grant the underwriter of the offering a 30-day option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions.

  • GlobeNewswire9 days ago

    Achaogen Submits Response to ASPR/BARDA Request for Information (RFI) for Antimicrobial Resistance Project BioShield

    Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that it has responded to a Request for Information (RFI) regarding antibacterial products with the potential to treat resistant biothreat pathogens.  The RFI was solicited by the Assistant Secretary for Preparedness and Response (ASPR) / the Biomedical Advanced Research and Development Authority (BARDA) under Project BioShield. The RFI specifically requested information on availabilities and capabilities for procuring, stockpiling and investing in the ongoing development of antibiotic products for commercial use for treatment of multiple biodefense indications, including pneumonic plague and tularemia, for which plazomicin has demonstrated preclinical efficacy.

  • GlobeNewswire9 days ago

    Achaogen Provides Update on Corporate Progress and Key Preliminary Fourth Quarter 2018 Results

    Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today shared certain key preliminary unaudited results for the fourth quarter ended December 31, 2018, and provided an update on its commercial and corporate activities. “As our previously announced review of strategic alternatives continues, I am pleased with the steady progress of the ZEMDRI commercial launch and especially the commitment of the entire company to bringing this important medicine to the infectious disease community,” said Blake Wise, Achaogen’s Chief Executive Officer.

  • Why are deep-pocketed biotechs cutting hundreds of jobs?
    American City Business Journals24 days ago

    Why are deep-pocketed biotechs cutting hundreds of jobs?

    Biotech companies' reasons differ for 600 job cuts over the past few months, but the numbers are jarring for an industry at the intersection of a strong cash position and groundbreaking science.

  • Could Achaogen, Inc.’s (NASDAQ:AKAO) Investor Composition Influence The Stock Price?
    Simply Wall St.2 months ago

    Could Achaogen, Inc.’s (NASDAQ:AKAO) Investor Composition Influence The Stock Price?

    If you want to know who really controls Achaogen, Inc. (NASDAQ:AKAO), then you'll have to look at the makeup of its share registry. Insiders often own a large chunk of Read More...

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Achaogen and Arcadia Biosciences

    NEW YORK, NY / ACCESSWIRE / December 11, 2018 / Arcadia Biosciences and Achaogen were two winners in the biotech arena on Monday. Achaogen soared over 20% on positive clearance news for the Thermo Scientific QMS Plazomicin Immunoassay. There was no remarkable news from Arcadia Biosciences to explain the jump.

  • GlobeNewswire3 months ago

    Recent Analysis Shows Best Buy Co., News Corporation, Semtech, Achaogen, Infosys, and Galapagos NV Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Dec. 06, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of AKAO earnings conference call or presentation 8-Nov-18 1:30pm GMT

    Q3 2018 Achaogen Inc Earnings Call

  • Health Care Digest: Genentech's blood cancer win, a boost for Gilead's HIV PrEP and a tiny IPO swings at antibiotics
    American City Business Journals3 months ago

    Health Care Digest: Genentech's blood cancer win, a boost for Gilead's HIV PrEP and a tiny IPO swings at antibiotics

    Why a South Bay company thinks it can disrupt a tough antibiotics market — and more in our weekly Health Care Digest.

  • GlobeNewswire3 months ago

    Achaogen Announces Multiple Plazomicin Presentations at the American Society of Health Systems Pharmacists (ASHP) Midyear Clinical Meeting

    SOUTH SAN FRANCISCO, Calif., Nov. 26, 2018 -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial.

  • Achaogen (AKAO) Reports Q3 Loss, Misses Revenue Estimates
    Zacks4 months ago

    Achaogen (AKAO) Reports Q3 Loss, Misses Revenue Estimates

    Achaogen (AKAO) delivered earnings and revenue surprises of 8.33% and -47.44%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press4 months ago

    Achaogen: 3Q Earnings Snapshot

    On a per-share basis, the South San Francisco, California-based company said it had a loss of $1.02. Losses, adjusted for restructuring costs, were 88 cents per share. The results beat Wall Street expectations. ...

  • 4 months after drug approval, Achaogen eyes fire sale
    American City Business Journals4 months ago

    4 months after drug approval, Achaogen eyes fire sale

    The company, which had hired close to 90 people leading up to its first drug approval, has been cutting jobs since the FDA said its antibiotic could be used in one type of infection but not another.